Research
Hormonal
Certain diabetes medications (GLP-1 agonists and SGLT2 inhibitors) promote weight loss, whereas others (insulin, sulphonylureas, thiazolidinediones) cause weight gain, influencing the choice of therapy in obese patients.
When choosing diabetes medication, ask your doctor about its effect on your weight. Some drugs (like GLP-1 agonists and SGLT2 inhibitors) help you lose weight, while others (like insulin and sulphonylureas) may cause weight gain. If you have obesity, your doctor should prioritize medications that support weight loss.
GoodQualifiesHIGH confidence
Common diabetes medications may lead to weight gain whereas others (such as glucagon-like peptide-1 agonists and sodium-glucose cotransporter-2 inhibitors) support weight loss.
Why this rating
Based on large-scale trials and consensus guidelines cited in the paper.
Source
Managing obesity in people with type 2 diabetes
Bonnie Grant et al. · Clinical Medicine · 2021
DOI 10.7861/clinmed.2021-0370
narrative_reviewCited 82×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Structured low-calorie total diet replacement (825–853 kcal/day) for 12–20 weeks followed by food reintroduction can induce remission of type 2 diabetes in a significant subset of patients, defined as HbA1c <48 mmol/mol without diabetic medications.Good
- Bariatric surgery is a safe, effective, and durable treatment for severe obesity in people with Type 2 Diabetes, leading to significant weight loss and high rates of diabetes remission, yet it remains significantly underutilized.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →